Health & Medical

No Serious CV Risks for Elderly After Pfizer COVID-19 Vaccine

Editor’s screen: Get essentially the most original COVID-19 news and steerage in Medscape’s Coronavirus Resource Center.

A French inhabitants-based entirely look affords extra evidence that the BNT162b2 Pfizer-BioNTech mRNA COVID-19 vaccine doesn’t invent bigger the transient menace for serious cardiovascular negative events in older of us.

The look showed no elevated menace of myocardial infarction (MI), stroke, or pulmonary embolism (PE) following vaccination in adults frail 75 years or older within the 14 days following vaccination.

“These findings regarding the BNT162b2 vaccine’s transient cardiovascular safety profile in older of us are reassuring. They must be taken into myth by doctors when brooding about imposing a third dose of the vaccine in older of us,” Marie Joelle Jabagi, PharmD, PhD, with the French Nationwide Company for Medicines and Health Merchandise Safety, Saint-Denis, France, urged | Medscape Cardiology.

The look was once printed as a learn letter online November 22 in JAMA.

The Pfizer-BioNTech mRNA vaccine was once the first SARS-CoV-2 vaccine authorized in France and has been widely passe in older of us. The section 3 trials of the vaccine showed no invent bigger in cardiovascular events, but older of us had been underrepresented within the trials.

As of April 30, 2021, nearly 3.9 million French adults frail 75 or older had obtained no decrease than one dose of the Pfizer COVID-19 vaccine and 3.2 million had obtained two doses.

The utilization of the French Nationwide Health Data Map linked to the nationwide COVID-19 vaccination database, Jabagi and her colleagues identified all unvaccinated or vaccinated adults frail 75 and older who had been hospitalized between December 15, 2020, and April 30, 2021, for acute MI, hemorrhagic or ischemic stroke, or PE.

All the contrivance during the 4.5-month look duration, 11,113 aged had been hospitalized for acute MI, 17,014 for ischemic stroke, 4804 for hemorrhagic stroke, and 7221 for PE. Of these, 58.6%, 54.0%, 42.7%, and 55.3%, respectively, had obtained no decrease than one dose of vaccine.

Within the 14 days following receipt of both dose, no critical elevated menace was once stumbled on for any final result, the investigators report.

The relative incidence (RI) for MI after the first and 2nd dose was once 0.97 (95% CI, 0.88 – 1.06) and 1.04 (95% CI, 0.93 – 1.16), respectively.

For ischemic stroke, the RI was once 0.90 after the first dose (95% CI, 0.84 – 0.98) and 0.92 (95% CI, 0.84 – 1.02) after the 2nd; for hemorrhagic stroke, the RI was once 0.90 (95% CI, 0.78 – 1.04) and 0.97 (95% CI, 0.81 – 1.15), respectively.

For PE, the RI was once 0.85 (95% CI, 0.75 – 0.96) after the first dose and 1.10 (95% CI, 0.95 – 1.26) after the 2nd dose.

There was once also no critical invent bigger for any of the cardiovascular events when the exposure menace window was once subdivided into 1 to 7 days and eight to 14 days.

“Evaluating the transient menace of hospitalization for excessive cardiovascular events after the BNT162b2 mRNA vaccine in older of us was once a precedence, especially after signals for hypertension and cardiovascular, thromboembolic, and hemorrhagic events had been issued from spontaneous notification files,” Jabagi urged | Medscape Cardiology.

“The outcomes of this nationwide look present extra stable evidence regarding the dearth of invent bigger of great cardiovascular negative events in older of us within the 14 days following both doses of the vaccine,” Jabagi talked about.

The French look helps a recent US look of larger than 6 million of us demonstrating that serious successfully being risks had been no more frequent within the first 3 weeks after Pfizer/BioNTech or Moderna COVID-19 vaccination in comparison with 22 to 42 days later.

As previously reported by Medscape Scientific News, mRNA vaccination was once now no longer connected to greater risks for Guillain-Barré syndrome, myocarditis/pericarditis, stroke, or 20 other serious outcomes.

The most original look had no explicit funding. Jabagi and colleagues gather declared no relevant conflicts of curiosity.

JAMA. Printed online November 22, 2021. Summary

Related Articles

Back to top button
%d bloggers like this: